Member Info for SocialistB

Will Hemo CAR-T get the go ahead before Christmas?

That is a good question.

I think and hope that it will.

For the simple reason that everyone, including the FDA would love the warm feeling that it is to give hope to patients who are running out of treatment options, and especially the warm feeling to do so before Christmas.

And if we are lucky, like in really lucky, then Mr. Sandler had no intention of announcing that the application has been submitted and instead, within the next 10 days, we get the MF of an RNS stating that we are now clinical and that the trial is about to start or even better has already started.

Now that would cause reasons for celebration in my eyes.

And it would be a surprise for everyone.

I think that could potentially be the best accelerator for the share price.

And then in January 2024 we start to hear more about CBR and CDX and it is going to be a drip feed to keep investors interested and on their toes.

How do you suggest that the news should land/be released to maximise the growth of the share price?

@Haywain

Thank you for reprinting your most excellent post again.

I hope you will keep it handy and reprint it regularly as we will eventually get an influx of new investors when the news hits the media.

And this post of yours outlines the potential so well.

Yesterday, I listened to this video where Hemogenyx was mentioned from back in September.

But the most interesting part for us is at the end where it is mentioned that several patents are expiring over the next 7 years.

https://www.lse.co.uk/media/HEMO/what-s-hot-19th-september-2023-wskk8hi97deejlg.html

With CDX, HEMO CAR-T and not least CBR all in development there could potentially be a bidding war going on within the next year.

And nice st that would be, personally I hope we can develop them ourselves.

Especially CBR.

What's your thoughts?

I think we have a lot to be grateful for with the raising earlier this week, but first a disclaimer.

Upon reading the RNS on Monday 27-11-2023, I thought it might be a good idea to invest the money allocated for Christmas for a quick profit.

Boy, was I wrong.

Being so close to becoming clinical, I failed to anticipate, that Hemogenyx might raise funds at this low level upon releasing a good RNS.

If I were to sell the shares I bought Monday, purely with the intention of a quick turnaround and small profit, there would be significantly less money for presents, food etc.

But, that is all on me.

I know, I should only invest with a 5-10 year time horizon, I have heard that so often that I ought to be able to recite it backwards if I was woken up in the middle of the night.

So after some effing off and feeling sorry for myself and reckoning that this is just typical of my luck, I decided to look on the bright side.

Whoever has decided Hemogenyx, needed to raise a sum in the region of 500.000 must surely have done their homework and calculated that that is what is needed to tie us over until we reach the anticipated significant milestone of becoming a clinical company.

So now no one has to fear that a placing is right around the corner to keep the lights on and no one can create FUD about it.

Not only that, but it is enough money to speed up the process of their ambitious plan to deliver expeditiously and also allocate further funding to CBR.

So, I choose to look at the raising as a positive, although I might be swearing a bit again if my Christmas dinner is going to have to consist of a chicken instead of a duck.

But hey, who am I to complain, there are unfortunately too many people out there who are far worse off and don't even have a roof over their heads this winter.

I wonder if Hemogenyx will be able to print trans-vaccenic acid (TVA) .

And if they can, would it have a positive effect on the HEMO Car-T

Interesting article to be found here:

https://www.msn.com/en-gb/health/other/eating-beef-staves-off-cancer-scientists-discover/ar-AA1kmrI6?ocid=msedgntp&pc=SCOOBE&cvid=34ecd75c23134207aaa87134e36c7c71&ei=12

The answer to your question is simple.

Insider trading.

With the knowledge they are sitting with, they are simply not allowed.

CEO, not VOE

I find Mr Sandler to have a high amount of integrity.

I am therefore baffled by people who calls for him to resign as CEO.

I cannot for the life of me see what a different CEO can bring to the table at this stage, other then an increased expense.

Mr. Sandler and team have acknowledged that the webpage is outdated, yet not done anything about.

There must be a reason for that.

Is it the expense? Is it their current workload? Do they prefer everything to be a bit cloak and dagger at the moment, or some totally different reason?

I don't know, I might newer find out, but I am sure there is a reason.

And that reason would still be in place with a different CEO, so there would not be a change in approach.

But the monthly expenditure for the payroll would have increased at a time where we have to work on a shoestring.

In my view that is not a smart move.

Mistakes have been made with financing, but we can all be doubed by others who have false intention.

And as Mr Sandler said afterwards he was glad for the money that they got and for that reason he did not regret it.

For me, that is integrity.

And I prefer that any day over a CEO spouting hot air to justify their pay.

We got all the info in official RNS's and we even occasionally get a tweet that shows something is happening.

And in my view, we are lucky that we have been able to hoover up shares at this level for as long as we have.

I am sure we are many who will have a lot to be thankful to Mr Sandler for in the years to come.

The science seems to be solid, based on the RNS's, there is no hot air statement, all is awesome in my view.

Will we need a new CEO, with more experience in running a business at some point in the future.

Yes, without a doubt.

But for now, at this stage, I commend Mr Sandler for being both the driving engine and VOE that he is.

It is a lot that is on his plate at the moment.

I was thrilled when I saw there was an RNS out, and I could not wait to read it.

Needless to say it did not contain the message that I was so hoping for. ( that HEMO is now clinical, or something down that line)

But, I assume that this is a housekeeping excersize before the big news starts rolling in next month.

Which coincidentally starts tomorrow.

Here's to hoping.

It's about a month ago we were told about Prevail Partners investing in Hemogenyx.

In the past we have been told that Mr Sandler would not reveal the partner that was lined up clinical trials before IND was sorted.

IND, has not Officially been sorted yet, but I believe that since the partner has been revealed it is as good as certain that it will be sorted successfully in the near future.

And I believe there is a good chance that it can happen this week as it is almost a month since we heard about Prevail.

And since then we have had fantastic news regarding CBR, well news can be discussed, but Mr Sandler has teasingly shown a device on social media that will be essential in the production of CBR.

And it is basically said an overgrown printer:-) and that is wonderful, because it makes it easy to scale up.

And Mr. Sandler and team have already had that planned for a while, just look at the following quote:

From RNS 13-7-2022

"Dr Vladislav Sandler, Co-Founder and CEO of Hemogenyx Pharmaceuticals said:

"I am thrilled to have moved into our customised and innovative lab space. The choice for our lab's continued growth was clear. With several current and future vivarium options, and the opportunity to collaborate with nearby world-class educational institutions including Columbia University and City College, the Mink Building offered an unmatched combination of advantages to operate and grow. Additionally, Janus was able to provide us with the future flexibility that is critical for us to continue to grow further."

I'll just repeat that again:

"Additionally, Janus was able to provide us with the future flexibility that is critical for us to continue to grow further."

As and if and when CBR has been proven, then Hemogenyx are ready to move and my understanding is that they will be able to move fast as there is no restriction from JANUS tying them in.

Quite the opposite, JANUS seems fully intent on helping the company grow.

The future is bright.

And I hope there will be a flash bang soon.

@Charles175

That is some impressive detective work you have done here, finding out which machine it was.

Very well done.

I am glad that you are a contributor on this board.

Showing if this piece of kit, was a wonderful little teaser from Mr Sandler in my view.

As investors, we now know that we do not need a huge factory hall with miles of pipes to manufacture CBR.

That is quite reassuring from a capital outlay point of view, although I am sure these machines does not come cheap either.

"A CBR mini-factory in action"

I like a message like that.

It looks like about 12 and 12 minutes left of the run when Mr. Sandler starts recording.

And more importantly, the run finishes at 2:10 AM.

That's in the middle of the night.

I call that commitment, as I assume that someone will have to be there and move it from the mini factory into a fridge or start testing it straight away.

In addition to potential news on the CBR front, I think the next couple of days are going to be interesting as we were informed on the 14-9-2023 that FDA had accepted the Clinical Hold Lift plan.

30 days are closing in (I hope)

As far as I am aware, the first day Hemogenyx was traded on the London Stock Exchange was on Monday the 9th of October 2017.

Wouldn't it be a poetic beauty if 6 years later, the company makes a seismic announcement in regard to any of our candidates.

The day is still young, so here is to hoping.

@HedgeHogarth

With every risk of sounding like a broken record;-)

I hope that it will merely be a break that you take, to take care of yourself.

Your contributions are much appreciated, not just by me, but by many I suspect.

Take a well-deserved break, I am looking forward to further good posts from you at some point in the future.

Stay awesome

@MrIndia

I disagree that the statements I have cut and pasted are vague.

I think they are very clear.

And that they tell us what news to expect to come.

“Attract high-level interest”

CBR is progressing and further resources will be allocated to this subject when time and money allow.

As today’s RNS was a half-year report, I expect it to be limited to what revolutionary news can be announced.

They are to follow in separate RNS’.

But hopefully these RNS’ will first come next month when I have a new allowance to invest and after the share price has dipped below 2 pence, so I can top up at a good price. (but hey, that is just me being selfish:-)

Do not forget, Mr Sandler can not control the share price, that is up to us investors and the Market Makers.

And today there was more selling than buying or the MM saw an opportunity to lower the price for one reason or another.

It does not matter to me one iota as I expect to be hugely rewarded for my patience.

And if I am lucky, that will be before the end of the year.

And if I am really lucky it will be within the next fortnight.

(But knowing my luck, I am not going to be that lucky)

If the following quote is Mr Sandler in his usual underplaying and overdelivering tone then this is ABSOLUTELY astonishing news, slash information that should comfort every investor.

“Meanwhile, the prospects for our other cutting-edge assets continue to be positive, and CBR in particular is beginning to attract real attention."

Further highlights in regard to CBR from the CBR section:

“Meanwhile, we have continued to work on our other major product candidates, in particular our Chimeric Bait Receptor”

“We have designed a set of novel CBR constructs to programme the immune cells that are responsible for innate immunity to eliminate viral infections.”

“Additionally, we have designed and currently test bait-macrophage engagers” (my emphasis is on the word TEST)

“The project has begun to attract high-level interest from authorities.”

“This interest is gratifying and, given our limited resources and the need to focus on our lead product HEMO-CAR-T, we have made considerable progress and plan to devote further internal resources to this project as soon as HEMO-CAR-T enters clinical trials.”

With HEMO-CAR-T planned to go into clinical trial later this year and the expected uplift in share price when that happens, I think the future is looking bright.

Unless there is a bad omen attached to HEMOGENYX we should be able to obtain funds for the further development of our products at a much higher share price than we got today.

Still down at this moment.

Hear hear for the latter option.

Hope to wake up to a brave new world tomorrow, and if that does not happen then a brand new updated website would be a nice consolation price:-)

@Cyrox

"Still peddling the idea that there was not a large premium paid by prevail for the privilege of running the trials. That is plain BS."

I would argue that Prevail haven't paid a dime.

In my view, they get to move money from one of their companies through HEMO and over in another of their companies.

In return they get just below 1percent if the shares in HEMO.

And they are likely to have forged a commercial bond that will last year's out in the future.

So they will essential Cary out the initial research for free, but in the long term, they are gaining big time.

But HEMO also gains from this deal.

Higher valuation and no or little upfront cost at this stage.

@JustHereForHemo

"if people on here or twitter dont agree? fair enough go buy something else, but dont pretend your smarter than a company whos very business model is investing in early clinical pharma and running trials"

This gotta be the qoute of the year.

Please keep them coming.

I assume that Mr. Sandler got to introduce CBR to a group of investors yesterday.

That was after establishing, through a partnership with Prevail, that a fair valuation point should be 6 pence and not sub 2 pence region.

So it is my hope that any potential professional investors accept to invest at 6 pence.

If we are unlucky, a discount is given from the 6 pence region, but at least that is better than the 2 pence region that it would have been by the end of last week.

And there is a good reason for professional investors to pay a premium if they see the potential game changers that Hemogenyx and CBR are.

It is better to give funds directly to the company, so it can work on its products than to buy the shares of me and any other John Doe.

Yes, currently they can buy the shares cheaper on the open market, but it would leave Hemogenyx with no additional funds to progress the development of their products.

And funds will be needed in the future.

Dengue is slowly getting a foothold in Europe, see the following link:

https://www.msn.com/en-gb/health/medical/deadly-virus-spreading-closer-to-uk-the-nine-symptoms-you-need-to-know/ar-AA1gT8Tp?ocid=msedgntp&cvid=28600c046abd42bcb46a8480f38a802c&ei=45

CBR is a potential candidate to solve that issue as it was RNS' on the 9th of January 2023 that CBR works against Dengue in the lab:

https://www.lse.co.uk/rns/HEMO/single-cbr-can-treat-multiple-viruses-btbliw44cz9mry8.html

But, Hemogenyx are not out of the lab yet.

And it will take funds to get it both to and through clinical trials.

These funds can be achieved either by investments (and thereby dilution) or by selling off HEMO CAR-T.

For now, I prefer further investment and dilution as long as it happens in the 6-pence region or above.